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Introduction 
Progressive supranuclear palsy (PSP) is a progressive neurodegenerative condition and the most common 
cause of atypical parkinsonism, with an estimated prevalence of 5-7 per 100,000 (1). The predominant clinical 
phenotype of PSP is Richardson’s syndrome (PSP-RS), which presents with an akinetic-rigid syndrome, falls, a 
vertical supranuclear gaze palsy and cognitive impairment with executive dysfunction. In recent years, the 
clinical heterogeneity of PSP has been highlighted by the description of two rarer clinical phenotypes in 
pathologically confirmed cases of PSP: PSP-Parkinsonism (PSP-P), characterised by asymmetric onset, tremor 
and a moderate initial therapeutic response to levodopa (2); and pure akinesia with gait freezing (PAGF), 
characterised by gradual onset of freezing of gait or speech, absent limb rigidity and tremor, no sustained 
response to levodopa and no dementia or ophthalmoplegia in the first 5 years of disease (3). 
Diagnosing PSP, particularly in the early stages of disease, may be challenging as there is a clinical overlap with 
Parkinson’s disease (PD), other atypical parkinsonian conditions such as multiple system atrophy (MSA) and 
other tauopathies including Alzheimer’s disease (AD), frontotemporal dementia (FTD) and corticobasal 
degeneration (CBD). Furthermore, most patients with PSP present with falls or non-specific visual symptoms, 
both of which are common in elderly subjects (4). A clinico-pathological study from 2002, which included 20 
cases of PSP, found that the positive predictive value of a clinical diagnosis of PSP was 80%, in contrast to the 
positive predictive value of a clinical diagnosis of PD which was 98.6% (5). However, a recent meta-analysis of 
11 clinico-pathological studies showed that the pooled diagnostic accuracy of PD was 80.6% (6), therefore 
similar to PSP. Furthermore, clinical criteria for the diagnosis of PSP according to the National Institute for 
Neurological Disorders and Society for PSP (7) have low diagnostic sensitivity, such that many patients with 
pathologically proven PSP will not have been identified according to clinical diagnostic criteria. New diagnostic 
criteria for PSP are expected to be published by the Movement Disorder Society in due course. For now, 
pathology at post-mortem remains the gold standard for diagnosing PSP. 
 
Tau in PSP  
The pathology of PSP is centred on the structural microtubule associated protein tau, encoded by MAPT. In 
PSP there is neuronal and glial accumulation of hyper-phosphorylated tau aggregates, with neurodegeneration 
(8). There are several possible links between tau pathology and neurodegeneration including the formation of 
toxic oligomers, disruption of normal microtubule function (9) and cell to cell spread of pathogenic tau (10).  
Autosomal dominant mutations in MAPT, lead to FTDP-17 (11), and common variation in MAPT predisposes to 
PSP (12).  
Tau pathology in PSP also involves an alteration in tau isoform homeostasis. Tauopathies can be classified 
according to the predominant isoform of tau that accumulates through alternative splicing of MAPT, leading to 
tau protein with 3 (3R) or 4 (4R) repeats of ~32 amino acids in the carboxy-terminus microtubule binding 
domain. 4R-tau is the dominant tau isoform in both PSP and CBD, in contrast to mixed 3R/4R-tau in AD (13). 
Tau hyperphosphorylation and microtubule dysfunction have been targeted in two recent clinical trials 
(14)(15), although both trials showed no effect on disease modification in PSP. 
 
 
 
 
CSF biomarkers used in the diagnosis of PSP 
Many cross sectional CSF studies have assessed whether CSF protein biomarkers can reliably differentiate PSP 
from healthy controls and patients with relevant differential diagnoses (see supplementary table for mean 
biomarker concentrations in PSP and control groups, and p-values for differences between groups). 
Tau and modified Tau 
Based on the pathology, one would expect that increased levels of CSF tau could be detected in PSP. The 
majority of CSF total or phosphorylated CSF tau (t-tau and p-tau) data reported in the literature is based on 
commercially available ELISAs, such as the INNOTEST assay (Fujirebio). In these assays, t-tau and p-tau 
measurements are dependent on anti-tau capture antibodies, such as AT120 and AT270 (pT181), specific for 
the mid-domain region of the protein, encoded by exons 4-8 (see figure 1).  
However, in established PSP disease there has been no observed consistent elevation of CSF t-tau or p-tau 
compared to healthy controls (16)(17). In addition, although Borroni and colleagues have shown lower levels 
of the CSF 33kDa/55kDa tau fragment ratio compared to healthy controls and other neurodegenerative 
conditions including FTD and AD (18)(19), this has subsequently been attributed to assay artefact (20). 
Regarding tau isoforms, Luk and colleagues showed decreased levels of CSF 4R-tau in PSP and AD groups 
compared to healthy controls (21), although further replication data is required.  
In contrast, raised CSF tau levels form a robust part of the diagnostic criteria for Alzheimer’s disease (22). 
However, it is uncertain why there is a difference between the CSF tau profile in PSP and AD considering that 
both conditions involve extensive neurofibrillary tangle pathology related to hyperphosphorylated tau protein. 
A potential explanation for the divergent tau profiles described above is that standard CSF tau ELISA might not 
detect elevations of specific tau species that are elevated in primary tauopathies such as PSP. In addition, the 
tau fragment profile is different in AD and PSP, which will determine epitopes and protein levels identified by 
ELISA. Importantly, most of tau in CSF appears to be in fragments containing N-terminal and/or mid-domain 
epitopes; virtually no full-length tau containing C-terminal sequences can be detected (23). Whether the 
concentrations of different fragments differ between different tauopathies is currently unknown. To 
investigate this possibility, Wagshal and colleagues used novel ELISAs (24)(see figure 1) targeting N-terminal 
and mid-domain epitopes to compare CSF tau concentrations in severity matched AD and PSP patients. This 
revealed that the PSP group had lower mean CSF N-terminal and mid-domain tau concentrations compared to 
the AD and control groups. In addition, receiver operating characteristics (ROC) analysis revealed that the N-
terminal fragment Tau12-BT2 assay was best at differentiating PSP from AD (area under the curve = 0.948, p < 
0.001). It is important to note that these novel ELISAs do not distinguish between 3R and 4R-tau isoforms.  It is 
hypothesised that the tau isoform profile may lead to an alteration in tau detectable in CSF in PSP and AD as 
4R-tau is released less readily from cells compared to 3R-tau (25).  
 
Non-tau related CSF biomarkers 
Non-tau related CSF biomarker candidates have also been studied extensively. The most promising of these 
have been Neurofilament light and heavy chain (NF-L and NF-H). Similarly to tau, neurofilaments are found in 
axons of neurons and are important components of the cytoskeleton. However, it appears that neurofilaments 
are highly expressed in large-calibre myelinated axons in white matter, whilst tau is predominantly expressed 
in thin unmyelinated axons of the cortex (26). Significantly higher CSF levels of both NF-L (17)(27) and NF-H 
(28) have been shown in patients with atypical parkinsonian conditions, including PSP, compared to controls 
and patients with PD. However, there were no significant differences between the individual atypical 
parkinsonian conditions. These results are thought to reflect the more extensive and rapid neuronal loss that 
occurs in atypical parkinsonian conditions compared to PD. The level of NF-L has also been shown to correlate 
with disease severity in PD, PSP (17), vascular dementia (VaD) (29) and FTD (30). 
Other CSF proteins of interest are soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ), and YKL-
40. sAPP is bound to the mitochondrial outer membrane and therefore may be implicated in mitochondrial 
dysfunction, which contributes to the development of neurodegenerative conditions. Similarly, YKL-40 has 
been implicated in neuroinflammation and neurodegeneration and is considered a marker of glial activation. A 
large cross sectional CSF study by Magdalinou and colleagues showed higher median levels of both NF-L and 
YKL-40, and lower median levels of both sAPPα and sAPPβ, in PSP compared to PD, AD, FTD and controls (31). 
The reason for such differences in the levels of sAPP and YKL-40 in PSP is unclear. Finally, there is limited 
evidence that CSF levels of glial fibrillary acidic protein (GFAP), a protein predominantly expressed in fibrillary 
astrocytes, are higher in PSP patients compared to controls (16). Replication in larger cohorts is required to 
further explore the significance of these alternative CSF biomarkers. For now, it should be reiterated that there 
is a lack of reproducible data for a biomarker that can reliably differentiate PSP from other neurodegenerative 
conditions.  
 
Blood biomarkers used in the diagnosis of PSP 
In contrast to the large number of CSF based diagnostic studies discussed above, we found only four blood 
based biomarker candidates that have been analysed in diagnostic studies involving PSP patients. Serum uric 
acid levels have been shown to be lower in PSP patients compared to controls (32), but this was later refuted 
by a similar cross-sectional study (33). MSA patients showed significantly higher levels of serum insulin-like 
growth factor-1 compared to controls in a study that also included PD and PSP patients (34). However, one 
study did reveal significantly elevated levels of both methylmalonate and homocysteine in all patient groups 
(PD, PSP, ALS) compared to controls (35). The significance of this is unclear but it has been hypothesised that 
elevated levels of methylmalonate and homocysteine are neurotoxic. 
 
Disease progression in PSP 
Longitudinal studies assessing the natural history of PSP reveal that the clinical disease progresses over time. 
Measuring change in neurodegenerative conditions is central to defining the effects of therapeutic 
intervention and disease biology. In assessing the PSP rating scale (PSPRS) score, Golbe and colleagues 
followed up 162 PSP patients over 11 years. They showed that the mean rate of progression was 11.3 points 
per year and the median actuarially corrected survival was 7.3 years from symptom onset to death. In 
addition, the PSPRS score was a good independent predictor of survival (36).  
However, such scales may be affected by intra- and inter-rater variability. In addition, their use in clinical trials 
may be hindered by differences in the time interval between pathological disease progression/response to 
therapeutics and change in clinical state.   
Therefore, the need for reliable disease progression biomarkers to complement clinical rating scales is clear. 
Predicting disease progression provides early prognostic information and may enable better powered clinical 
trials with more homogenous groups, and give insights into the mediators of disease progression. From a 
therapeutic trials perspective, measuring non-clinical biomarkers of disease progression may enable early 
demonstration of target engagement. However, no studies have shown that individual biomarkers are better 
than clinical scales at tracking disease progression and so, for now, clinical scales remain the only reliable 
options available. In addition, there are certain limitations encountered with CSF and blood as sources of 
biomarkers as lumbar puncture is an invasive procedure with potential complications, while protein 
concentrations in blood may not reflect the pathological changes in the brain due to variations in blood-brain 
barrier permeability. 
Here we review the reliability of CSF and blood biomarkers in predicting and tracking clinical disease 
progression in PSP. As well as summarising the literature to date, we also discuss the road ahead. 
 
Methods 
We performed a PubMed/Medline search and limited searches to studies reported in English, comparing PSP 
patients to patients with other neurodegenerative conditions and/or healthy controls (see figure 2) up until 
February 2017. Studies predicting disease progression were defined as longitudinal, prospective studies with 
baseline blood and/or CSF analysis and clinical assessment followed by at least one subsequent clinical 
assessment, in which the baseline measures were correlated with subsequent progression. Studies tracking 
disease progression are defined as longitudinal, prospective studies with baseline blood and/or CSF analysis 
and clinical assessment followed by at least one subsequent blood and/or CSF analysis and clinical assessment, 
in which longitudinal measures were assessed for disease progression. 
We used searches including the terms ‘progressive supranuclear palsy’, ‘PSP’, ‘parkinsonism’, 
‘neurodegenerative diseases’, ‘atypical Parkinsonism’, ‘blood’, ‘plasma’, ‘serum’, ‘CSF’, ‘CSF biomarkers’, 
‘biomarker’, ‘NFL’, ‘tau’, ‘tauopathies’, ‘prospective’, ‘longitudinal’, 'consecutive', ‘serial’, ‘predicting’, 
‘tracking’, ‘progression’ and ‘disease progression’. Further references were found manually from identified 
publications. 
All identified studies met a minimum quality score defined by the presence of: at least 5 PSP patients included 
in the study, with clearly defined diagnostic criteria; a clearly defined primary outcome of the study; a 
minimum period of 10 months between the first and last clinical assessment, lumbar puncture and/or blood 
test; clearly defined components of the clinical assessments used in the study; clearly defined CSF sampling 
protocol and use of assays; appropriate recording of statistical analysis used to interpret results.  
 
 
Results 
We identified five longitudinal studies in total. Four of the identified studies tracked clinical disease 
progression in PSP patients using CSF and/or blood biomarkers, including one study that was derived from the 
Davunetide clinical trial (14). One study predicted clinical disease progression using blood biomarkers. We did 
not identify any studies that used CSF biomarkers to predict progression.  
 
Tracking disease progression in PSP 
CSF 
Most, but not all of the identified CSF studies (see table 1 for statistics) showed that the levels of CSF NF-L 
increased over time and correlated with clinical disease progression. The one exception was the study by 
Constantinescu and colleagues who showed that consecutive CSF analysis revealed relatively stable levels of 
NF-L and GFAP over time in all of the investigated parkinsonian groups (37). 
In contrast, Backstrom and colleagues found that CSF NF-L levels was stable in PD patients but rose by almost 
30% in PSP patients, over one year when compared to baseline CSF levels  (38). As the majority of study 
participants consisted of PD patients, follow up clinical assessment and analysis of whether CSF biomarkers 
could predict clinical disease progression was limited to this group and revealed that the baseline triad of high 
NF-L, low Aβ1-42 and high heart fatty acid-binding protein (HFABP) indicated a high risk of developing 
Parkinson’s disease dementia (PDD). Similarly, a small subgroup of patients, who were part of a larger study by 
Magdalinou and colleagues, underwent serial CSF analysis and clinical examination to assess disease 
progression over the course of 1 year. Clinical examination consisted of measuring disease severity using the 
Hoehn and Yahr (H&Y) staging system and assessing clinical rating scores using the PSPRS and Mattis Dementia 
Rating Scale (DRS-2). At 1 year they found an increase in H&Y score and PSPRS, and a decrease in DRS-2. These 
changes were associated with a mean change in levels of NF-L (+540ng/L) (31). 
                                                                                                                         
A major source of longitudinal data has come from recent therapeutic trials in PSP. A small subset of patients 
in the Davunetide trial had serial CSF analysis, measuring levels of CSF Aβ42, t-tau, p-tau and NF-L. Although 
there were no differences in rates of change between the Davunetide and placebo groups, NF-L was the only 
CSF biomarker whose concentration showed a statistically significant change over time, with a mean increase 
in concentration by 755ng/L when Davunetide and placebo patients were grouped together. Although the 
mean increase in CSF NF-L was lower in the Davunetide group compared to the placebo group (+494ng/L vs 
+922ng/L), this difference was not statistically significant (p = 0.43). However, the role of CSF NF-L in tracking 
disease progression was once again highlighted by the fact that the one year change in CSF NF-L levels 
correlated with an increase in the oculomotor subscale of the PSPRS (14). 
CSF biomarker Research Group n number of PSP 
patients 
Median time between 
first and last samples 
(months) 
Mean interval 
change in 
biomarker 
concentration 
(median baseline 
concentration) 
Associated change in 
clinical marker 
(correlation of change in 
biomarker vs change in 
clinical marker) 
NF-L Constantinescu et al (37) 14 14.5 NS 
 (956.5ng/L) 
Not applicable 
Backstrom et al (38) 9 12 +1333ng/L 
(2357ng/L) 
Not assessed 
Magdalinou et al (31) 9 12 +540ng/L 
(2219ng/L) 
1.2 point increase in 
mean H&Y score and 
14.2 point increase in 
mean PSPRS score † 
Boxer et al (14) 22  12 +755ng/L – 
including active 
treatment and 
placebo patients 
(5185pg/ml) 
11.3 point increase in 
mean PSPRS score. 
Increase in NF-L 
concentration correlated 
with increase in mean 
oculomotor subscale of 
PSPRS (Spearman’s rho = 
0.609; p = 0.003)  
GFAP Constantinescu et al (37) 14 14.5 NS 
 (760ng/L) 
Not applicable 
sAPPβ 
 
Magdalinou et al (31) 9 12 NS 
(256ng/ml) 
Not applicable 
Aβ42  Boxer et al (14) 22 12 NS 
(384ng/L) 
Not applicable 
Backstrom et al (38) 9 12 NS 
(486ng/L) 
Not applicable 
t-tau Boxer et al (14) 22 12 NS 
(59.5ng/L) 
Not applicable 
Backstrom et al (38) 9 12 NS 
(240ng/L) 
Not applicable 
p-tau Boxer et al (14) 22 12 NS 
(24.5ng/L) 
Not applicable 
Backstrom et al (38) 9 12 NS 
(39ng/L) 
Not applicable 
α-synuclein Backstrom et al (38) 9 12 NS 
(565ng/L) 
Not applicable 
HFABP Backstrom et al (38) 9 12 NS 
(450ng/L) 
Not applicable 
† Correlation between change in biomarker and change in clinical marker not calculated 
NS No significant change in biomarker concentration over time 
Table 1: CSF biomarkers used to track disease progression in PSP 
 
Blood 
Longitudinal fluid biomarker analysis in the Davunetide study (14) also included plasma NF-H which did not 
show any significant change in concentration over 1 year, with a median baseline concentration of 760ng/L.   
 
Predicting disease progression in PSP  
Blood 
We identified a recent longitudinal study of PSP patients by Rojas and colleagues which assessed the ability of 
baseline plasma NF-L to predict a change in clinical measures using age, gender and baseline MMSE adjusted 
mixed linear models. Similarly, age and gender controlled Pearson’s partial correlations were determined 
between baseline plasma NF-L levels and changes in regional and whole brain volume. The study showed that 
high baseline plasma NF-L levels (see table 2 for statistics) predict more severe neurologic, cognitive and 
functional decline at 1 year follow up, as well as changes in whole brain and SCP volume loss (39). In addition, 
plasma and CSF NF-L were significantly correlated (r = 0.74, p = 0.002). 
 
Plasma 
biomarker 
Research Group n number of PSP 
patients 
Mean baseline 
biomarker 
concentration (ng/L) 
Mean baseline 
clinical marker 
score 
Statistical analysis of 
baseline biomarker 
predicting disease 
progression 
NF-L Rojas et al (39) 147 43.7 High NF-L group 
PSPRS – 40.0 
Low NF-L group 
PSPRS – 38.1 
High baseline plasma NF-
L (defined as 
>36.7pg/ml) group had 
more severe worsening 
of PSPRS score over 1 
year vs low baseline 
plasma NF-L (defined as 
<36.7pg/ml) group, p = 
0.02  
Table 2: Blood biomarkers used to predict disease progression in PSP 
 
 
Discussion 
There is very limited evidence that CSF and blood biomarkers may have a role in predicting and/or tracking 
disease progression in PSP. Overall, the studies identified suggest that CSF NF-L tracks clinical disease 
progression over time, and that this correlates with the PSPRS score. A particularly interesting question that 
has not been looked at in previous studies is whether or not there are differences in the change in NF-L over 
time in early vs late stage disease. Other potential markers of tracking disease progression that had favourable 
results included CSF sAPPβ and GFAP. Of interest, a recent study analysed NF-L changes in plasma, CSF and 
brain of a variety of mouse models of proteopathic (α-synuclein, tau and β-amyloid) neurodegenerative 
diseases. Plasma and CSF NF-L levels were strongly correlated, and NF-L increases coincided with the onset and 
progression of corresponding proteopathic lesions in the brain. In addition, experimental induction of α-
synuclein lesions increased plasma and CSF NF-L levels, whilst blocking β-amyloid lesions attenuated the NF-L 
increase (40). The study therefore concluded that plasma and CSF NF-L may serve as both a marker of disease 
progression and also as a biomarker for treatment response in proteopathic neurodegenerative diseases. With 
regards to predicting disease progression, Rojas and colleagues showed that high baseline plasma NF-L is able 
to predict more severe functional decline (39). 
However, when compared to the volume of cross sectional diagnostic studies that have been carried out (a 
recent review by Magdalinou and colleagues on the diagnostic use of CSF biomarkers in parkinsonian 
conditions yielded 78 studies (41)), there is a clear lack of longitudinal fluid biomarker data on the topic of 
disease progression in PSP. Of the five studies that were identified, most had small subject numbers, were 
limited to only 1 year of follow up and exhibited heterogeneity in both the disease and control groups. In 
contrast, there appears to be a greater depth of studies looking at longitudinal brain changes in PSP patients 
using a variety of conventional and non-conventional MRI modalities (42)(43)(44)(45). Another major 
drawback is the lack of combined longitudinal CSF and blood studies - the Davunetide study was the only 
longitudinal study identified to achieve this.  
Other potential future directions on the topic in question include the use of new imaging modalities, including 
PET imaging with Tau ligands (46) and further studies on the role of blood based biomarkers. Of note, future 
studies may be able to achieve ultra-sensitive measurement of fluid biomarkers by utilising novel technologies 
such as single molecule array (SIMOA) (47), single molecular counting (SMC) (48) and proximity extension 
assay (PEA) (49). Novel assays, such as the real-time quaking-induced conversion assay (RT-QuIC), can be used 
to study misfolded protein biomarkers including tau and β-amyloid (50). 
This review has highlighted the need for longitudinal studies with large subject numbers that use combined 
(CSF, blood and imaging) biomarkers. Such studies will first of all aim to replicate the findings of existing 
longitudinal data on the role of biomarkers in tracking and predicting disease progression. There is also the 
potential to identify the first reliable PSP-specific biomarker, which may further improve our understanding of 
the underlying disease mechanisms. We hope that such biomarkers can be used in clinical trials of novel 
therapeutic targets, where the role of biomarkers as an objective measure of treatment response remains 
important. We also aim to determine the role of genetics in predicting disease progression and its association 
with the biomarkers in question. We will carry out these studies using patient data from the PROSPECT study, 
a UK wide, multi-centre longitudinal study that follows up patients over 5 years.  
Figure 1 legend: Modified figure from Wagshal et al (24) highlighting the differences in capture antibodies 
between standard (INNOTEST) and novel tau ELISAs 
Figure 2 legend: Flow diagram outlining the selection procedure to identify the 5 studies which were included 
in this review 
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